Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient
Linda Rogers(Mount Sinai Health System), Zuzana Diamant(Lund University), Miloš Jeseňák(Martin University Hospital), Nicola A. Hanania(Baylor College of Medicine), Sven Seys(Rega Institute for Medical Research), Leif Bjermer(Lund University)
Cited by 51
Related Papers
Lebrikizumab Treatment in Adults with Asthma
|New England Journal of Medicine|2011|1.5k
MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
|Journal of Allergy and Clinical Immunology|2010|578
Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy
|Annals of Internal Medicine|2011|550
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
|The Lancet Respiratory Medicine|2016|465
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
|New England Journal of Medicine|2023|452